Pharmaxis logo
  • About
    • Our People
      • Scientific Advisory Board
    • Partners and Distributors
    • Corporate Directory
    • Corporate Governance
    • COVID-19: Information for People Using Bronchitol
  • Product Pipeline
    • Drug Discovery
    • Amine Oxidase Platform
      • Oral pan-LOX Inhibitor (PXS-5505)
      • LOXL2 Inhibitors (PXS-5382)
      • SSAO Inhibitor (PXS-4728)
      • Other Amine Oxidase Inhibitor Programs
    • Other Pipeline Assets
      • Orbital® Dry Powder Inhaler
    • Publications & Posters
    • Patents
  • Approved Products
    • Manufacturing Facilities
    • Bronchitol®
      • Cystic Fibrosis
      • Clinical Trials
      • Publications
      • Patents
      • Partners and Distributors
      • COVID-19: Information for People Using Bronchitol
    • Aridol®
      • Asthma
      • Clinical Trials
      • Publications
      • Patents
      • Distributors
  • News
  • Patients & Prescribers
  • Contact
    • Media
    • Follow us
Investor Centre Investor Centre
  • News
  • ASX Announcements
  • Quarterly Updates
  • Annual and Half Year Reports
  • Investor Presentations
  • Shareholder Services
  • Upcoming Events
  • Analyst Coverage
  • Major Shareholders
  • Corporate Governance
  • Subscribe to our emails or follow us
  • Videos and Podcasts

News Feeds

News Feeds

News Feeds

  • All News
  • All Pharmaxis News
  • Annual Reports
  • ASX Announcements
  • Investor Presentations
  • Quarterly Updates
  • © Copyright 2021 Pharmaxis Ltd
  • Design by Solutions Outsourced
  • Legal
  • Glossary
Announcement icon

COVID-19: Information for People Using Bronchitol

Read more Dismiss